Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.
Saved in:
| Title: | Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA. |
|---|---|
| Authors: | Blauvelt, Andrew1 (AUTHOR), Shi, Nianwen2 (AUTHOR), Somani, Najwa3 (AUTHOR), Burge, Russel3,4 (AUTHOR), Zhu, Baojin3 (AUTHOR), Ridenour, Terri3 (AUTHOR), Kern, Scott3 (AUTHOR), Lew, Carolyn2 (AUTHOR), Zimmerman, Nicole2 (AUTHOR), Murage, Mwangi3 (AUTHOR) murage_mwangi_james@lilly.com |
| Source: | Clinical Drug Investigation. Mar2023, Vol. 43 Issue 3, p185-196. |
| Database: | SPORTDiscus with Full Text |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 11732563 |
|---|---|
| DOI: | 10.1007/s40261-022-01240-9 |
